Fulcrum Therapeutics' (FULC) FTX-6058 Data is Strong Start, Sets Stage for In-Patient Trial in 4Q21 - Analyst

Fulcrum Therapeutics Inc. (FULC) Prices 6.6M Share Offering at $19/sh

Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has priced an underwritten public offering of 6,600,000 shares of its common stock at a public offering price of $19.00 per share, for total gross proceeds of approximately $125 million, before deducting underwriting discounts and commissions and offering expenses payable by Fulcrum. All of the shares in the offering are being sold by Fulcrum. In addition, Fulcrum has granted the underwriters a 30-day option to purchase up to 990,000 additional shares... More

Fulcrum Therapeutics Inc. (FULC) Halted on LUDP, Up 114%

Fulcrum Therapeutics Inc. (NASDAQ: FULC) Halted on LUDP, Up 114%

Fulcrum Therapeutics (FULC) PT Raised to $45 at Stifel

Stifel analyst Dae Gon Ha raised the price target on Fulcrum Therapeutics (NASDAQ: FULC) to $45.00 (from $39.00) while maintaining a Buy rating.

Fulcrum Therapeutics Inc. (FULC) Climbs 48%

Fulcrum Therapeutics Inc. (NASDAQ: FULC) Climbs 48%

Fulcrum Therapeutics Inc. (FULC) Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease

Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced positive interim results from the ongoing single- and multiple-ascending dose (SAD and MAD) Phase 1 trial with FTX-6058 in healthy adult volunteers. FTX-6058 is an investigational, potent, and selective small molecule inhibitor of EED designed to... More

Fulcrum Therapeutics Inc. (FULC) Tops Q2 EPS by 2c

Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q2 EPS of ($0.60), $0.02 better than the analyst estimate of ($0.62). Revenue for the quarter came in at $4.3 million versus the consensus estimate of $1.6 million.

For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.